Home › Type 2 Diabetes › NCT05933161

A Study of Glycemic Control in Left Ventricular Assist

GLYcemic Control Evaluation by Continuous Glucose Monitor Compared With a1C in Left Ventricular Assist Device-supported Patients (GLYCEM1C-LVAD)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010
* Diagnosis of type II diabetes mellitus
* Any antihyperglycemic regimen
* Greater than 3 months out from LVAD implantation
* Capable of utilizing smartphone device for LibreLink app for uploading glycemic data
* Patients may be enrolled who have preexisting CGM in place.

Exclusion Criteria:

* Type I diabetics
* Unable to return at 3 month evaluation
* Unwillingness to participate

About the study

The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.

What is being tested

• Freestyle Libre 3 Continuous Glucose Monitor (CGM) (device)

Sponsor: Mayo Clinic · Participants: 20 · Started: Nov 10, 2023

Contact the study team

• Sarah Schettle, PA-C · Phone: (507) 293-1375
• Andrew Rosenbaum, MD · Phone: (507) 284-0783

Official record on ClinicalTrials.gov — NCT05933161

Locations in the U.S.

Conditions

• Type 2 Diabetes
• Hyperglycemia
• Hypoglycemia

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.